Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Policosanol - Nutraceuticals World
Research

Policosanol

Indication: Hypercholesterolemia/hyperlipidemia

Source: JAMA, May 17, 2006;295(19):2262-2269.

Research: Researchers performed a multicenter, randomized, placebo-controlled, parallel-group trial of 143 patients with hypercholesterolemia or combined hyperlipidemia having a baseline LDL cholesterol of 150 mg/dl and either no or one cardiovascular risk factor other than known coronary heart disease, or baseline LDL-C levels of between 150 and 189 mg/dl and two or more risk factors. This open-label six-week study had a diet run-in phase followed by a double-blind 12-week treatment phase after randomization into five groups: 10, 20, 40, or 80 mg/dl of policosanol or placebo.

Results: In none of the five treatment groups did LDL-C levels decrease more than 10% from baseline. Further, re-searchers found no statistically significant difference between policosanol and placebo. In none of the secondary outcome measures, namely total cholesterol, HDL-C, very low LDL, triglycerides, lipoprotein and a ratio of total or LDL-C to HDL C, were there any significant effects of policosanol. Researchers concluded that in patients with hypercholesterolemia or combined hyperlipidemia, the sugar cane-derived policosanol in usual and high doses does not demonstrate a reduction in lipid levels beyond placebo.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters